A subcutaneous injection of teclistamab elicits responses in 74% of patients with relapsed/refractory multiple myeloma, offering a promising treatment option for patients with poor prognoses. The study's results suggest that teclistamab takes a similar approach to cellular therapies but is more convenient and faster to administer.
The combination of venetoclax with chemotherapy improves outcomes for patients with AML and MDS, with a promising overall response rate and acceptable safety profile. Venetoclax also demonstrates efficacy in treating high-risk MDS when combined with azacitidine.
Researchers from RUDN University have developed a new method to analyze cytokines in nasal swabs to predict disease flow and prevent complications in asthma patients with accompanying diseases. The study found that monitoring specific cytokine profiles can help identify dangerous tendencies and allow for timely intervention.
A recent study by Dana-Farber Cancer Institute scientists has found that clonal hematopoiesis can confer a health benefit in the setting of allogeneic stem cell or bone marrow transplants. Patients who received transplants from older donors with CH had a lower risk of relapse and longer survival compared to those without CH.
A recent study presented at the 2020 ASH meeting demonstrated that Gazelle's integrated anemia-SCD test has a high sensitivity and specificity for detecting anemia, with over 92.3% accuracy. The test is expected to be available in mid-2021 and has the potential to improve disease management in low-resource settings.
Axicabtagene ciloleucel (axi-cel) achieved undetectable cancer levels in nearly 80% of patients, and durable responses in most participants. The therapy demonstrated improved response rates for follicular lymphoma compared to marginal zone lymphoma.